Diseases affected by local microvascular insufficiency (alopecia, skin aging, erectile dysfunction)
Conditions
Interventions
Drawing peripheral blood as material for conditioned medium preparation and various clinical tests.
Administration of conditioned medium subcutaneously or intramuscularly by injection under anesthesia
Sponsors
Matsubara Shinobu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Patients with written informed consent. -Patiens are at least 18 years of age and less than 85 years old at the time of informed consent. -Patients affected alopecia and wish to receive regenerative therapy. -Patients with facial wrinkles, dryness, and other skin symptoms associated with local microvascular insufficiency and wish to receive regenerative therapy. -Patients with ED (IIEF-5 score 21 or less) who wish to be treated with regenerative medicine.
Exclusion criteria
Exclusion criteria: -Patients with severe anemia (Hb -Patients with signs of infection in the area of hair loss. -Patients with skin diseases caused by infections such as herpes and pyoderma gangrenosum. -Patients with structural defects of the penis (penile curvature, fibrosis of the penis, Peyronie's disease, etc.) -Patients with diseases that may predispose to priapism (sickle cell anemia, multiple myeloma, leukemia, etc.) -Patients whose PSA level exceeds the age-group-specific cutoff values at the initial visit. (50-64 years: 3.0 ng/mL, 65-69 years: 3.5 ng/mL, 70 years and older: 4.0 ng/mL) However, the following patients, who are considered to have PSA recurrence, are included even if more than five years have passed since their prostate cancer was cured. -Patients with persistently elevated PSA levels -Patients with newly diagnosed disease, including local recurrence or new metastatic lesions. -Patients who have undergone radical prostatectomy and whose PSA level exceeds 0.2 ng/mL at the initial visit. -Patients with a PSA level exceeding 2.0 ng/mL at the initial visit after radical radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of multiple dose injection of Conditioned medium side effects, adverse events, serious advese events | — |
Contacts
Public ContactSatoshi Fujimura
Juntendo University
Outcome results
None listed